Sep 30, 2025 6:44 pm
Researchers at Queen Mary University of London’s School of Biological and Behavioural Sciences, using the simple fission yeast as a model, have shown that a new target of rapamycin (TOR) inhibitor, rapalink-1, which is in development against cancer, prolongs chronological lifespan.
The study, headed by Charalampos Rallis, PhD, revealed TOR-regulated genes with unknown roles in aging, and could shed new light on how drugs and natural metabolites can influence lifespan through the TOR pathway.
Leave a reply